Clinical trial
A Phase 1, Controlled, Open-label, Single Dose, Dose-escalation, Clinical Proof-of-concept Study of MRI Enhanced With ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in Patients With Brain Amyloid Deposits as Demonstrated by Amyloid PET
NCT05453539 is registered in ClinicalTrials.gov with Alzeca Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Controlled, Open-label, Single Dose, Dose-escalation, Clinical Proof-of-concept Study of MRI Enhanced With ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in Patients With Brain Amyloid Deposits as Demonstrated by Amyloid PET
- Lead sponsor
- Alzeca Biosciences, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- November 9, 2022
- Completion date
- November 8, 2024
- Enrollment
- 16 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.